Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: A 12-week, open-label, post-marketing surveillance study

Drug Safety

Volumn 31, Issue 6, 2008, Pages 505-514

  Michel, Martin C ^a,d   Wetterauer, Ulrich ^b   Vogel, Monika ^c   De La Rosette, Jean J M C H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Astellas Pharma GmbH   (Germany)

^d Sport Medical Center   (Netherlands)

Author keywords

Cardiovascular disorders; Heart rate; Muscarinic receptor antagonists, adverse reactions; Overactive bladder; Postmarketing surveillance; Solifenacin, adverse reactions; Solifenacin, general

Indexed keywords

ESTROGEN; HERBACEOUS AGENT; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

ACUTE ABDOMEN; ADULT; AGED; ARTICLE; BACTERIURIA; BLOOD PRESSURE MEASUREMENT; CARDIOTOXICITY; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONSTIPATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; FLICKERING VISION; GENERALIZED EDEMA; GERMANY; GLUCOSURIA; HEMATURIA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LEUKOCYTURIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSTATITIS; PROTEINURIA; RISK ASSESSMENT; TACHYCARDIA; URINARY TRACT INFECTION; VISUAL DISORDER; XEROSTOMIA;

AGED; AGED, 80 AND OVER; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; FEMALE; GERMANY; HEART RATE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PRODUCT SURVEILLANCE, POSTMARKETING; QUINUCLIDINES; TETRAHYDROISOQUINOLINES;

EID: 43749115354     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831060-00005     Document Type: Article

References (19)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78
2. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6
3. Stewart WF, van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36
4. Herbison P, Hay-Smith J, Ellis G, et al. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003; 326: 841-4
5. Chapple C, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005; 48: 5-26
6. Brodde O-E, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999; 51: 651-89
7. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 464-70
8. Michel MC, Oelke M, Zinner N. Novel muscarinic antagonists to treat incontinence and/or overactive bladder. Drug Discov Today: Ther Strat 2005; 2: 1-6
9. Payne CK. Solifenacin in overactive bladder syndrome. Drugs 2006; 66: 175-90
10. Ikeda K, Kobayashi S, Suzuki M, et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 97-103
11. Michel MC, Goepel M. Treatment satisfaction of patients with lower urinary tract symptoms: randomised controlled trials vs real life practice. Eur Urol 2000; 38 Suppl. 1: 40-7
12. Michel MC, Schneider T, Krege S, et al. Do gender or age affect the efficacy and safety of tolterodine? J Urol 2002; 168: 1027-31
13. Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50: 823-30
14. Poller U, Nedelka G, Radke J, et al. Age-dependent changes in cardiac muscarinic receptor function in healthy volunteers. J Am Coll Cardiol 1997; 29: 187-93
15. Brodde O-E, Konschak U, Becker K, et al. Cardiac muscarinic receptors decrease with age: in vitro and in vivo studies. J Clin Invest 1998; 101: 471-8
16. Brusa R, Gamalero SR, Genazzani E, et al. In primary neuronal cultures muscarinic m1 and m3 receptor mRNA levels are regulated by agonists, partial agonists and antagonists. Eur J Pharmacol 1995; 289: 9-16
17. 3-muscarinic acetylcholine receptor mRNA and protein in cultured cerebellar granule cells. Mol Pharmacol 1993; 44: 940-9
18. Nilvebrant L, Ekström J, Malmberg L. Muscarinic receptor density in the rat urinary bladder after denervation, hypertrophy and urinary diversion. Acta Pharmacol Toxicol 1986; 59: 306-14
19. Abrams P, Andersson K-E, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006; 148: 565-78